Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10872139 | 0.83 | HTR2A (0.51) | MEN1ALDH1A1RAB9AKMT2AHTR2A | |
| SCHEMBL11508628 | 0.77 | ADRA2A (0.61) | MEN1RAB9AKMT2AHTR2ADRD2 | |
| SCHEMBL24746500 | 0.75 | HPGD (0.66) | MEN1ALDH1A1RAB9AKMT2AHTR2A | |
| SCHEMBL10871232 | 0.74 | HTR2A (0.50) | MEN1ALDH1A1RAB9AKMT2AHTR2A | |
| SCHEMBL9033157 | 0.74 | HTR2A (0.74) | MEN1ALDH1A1RAB9AKMT2AHTR2A | |
| SCHEMBL10870803 | 0.73 | HPGD (0.56) | MEN1ALDH1A1RAB9AKMT2AHTR2A | |
| SCHEMBL10867950 | 0.73 | HTR2A (0.49) | MEN1ALDH1A1RAB9AKMT2AHTR2A | |
| Hydrochloric Acid SCHEMBL10867806 | 0.73 | HTR2A (0.49) | MEN1ALDH1A1RAB9AKMT2AHTR2A | |
| SCHEMBL6465788 | 0.73 | HTR2A (0.88) | RAB9AHTR2ADRD2DRD3ADRA2A | |
| SCHEMBL24746494 | 0.73 | ADRA2A (0.61) | HTR2AOPRM1OPRD1DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592350-B2 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | ORION CORPORATION (FI) | 2009-09-22 | — | — | US | disclosed |
| US-20070293527-A9 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | ORION CORPORATION (FI) | 2007-12-20 | — | — | US | disclosed |
| EP-1490361-B1 | POLYCYCLIC COMPOUNDS AS POTENT ALPHA2-ADRENOCEPTOR ANTAGONISTS | ORION CORP (FI) | 2007-10-03 | — | — | EP | disclosed |
| US-20060094740-A1 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | DIN BELLE DAVID | 2006-05-04 | — | — | US | disclosed |
| EP-1490361-A1 | POLYCYCLIC COMPOUNDS AS POTENT ALPHA2-ADRENOCEPTOR ANTAGONISTS | ORION CORPORATION (FI) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003082866-A1 | POLYCYCLIC COMPOUNDS AS POTENT ALPHA2-ADRENOCEPTOR ANTAGONISTS | ORION CORPORATION (FI) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094740-A1 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | ADRB2, ADRA2A, ADRB1 | MEN1 1187/4885ALDH1A1 1315/4885RAB9A 1968/4885 |
| US-20070293527-A9 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | ADRB2, ADRA2A, ADRB1 | MEN1 1187/4885ALDH1A1 1315/4885RAB9A 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.